La Rosée P - Search Results

1

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

La Rosée P, Shen L, Stoffregen EP, Deininger M, Druker BJ. La Rosée P, et al. Hematol J. 2003;4(6):413-9. doi: 10.1038/sj.thj.6200297. Hematol J. 2003. PMID: 14671613

2

Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.

O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ. O'Dwyer ME, et al. Among authors: la rosee p. Semin Hematol. 2002 Apr;39(2 Suppl 1):18-21. doi: 10.1053/shem.2002.33612. Semin Hematol. 2002. PMID: 12012318 Review.

3

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.

La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. La Rosée P, et al. Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6. Exp Hematol. 2002. PMID: 12135670 Free article.

4

Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. La Rosée P, et al. Cancer Res. 2002 Dec 15;62(24):7149-53. Cancer Res. 2002. PMID: 12499247

5

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Corbin AS, et al. Among authors: la rosee p. Blood. 2003 Jun 1;101(11):4611-4. doi: 10.1182/blood-2002-12-3659. Epub 2003 Feb 6. Blood. 2003. PMID: 12576318 Free article.

6

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. La Rosée P, et al. Blood. 2004 Jan 1;103(1):208-15. doi: 10.1182/blood-2003-04-1074. Epub 2003 Aug 21. Blood. 2004. PMID: 12933582 Free article.

7

Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.

La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW. La Rosée P, et al. Clin Cancer Res. 2006 Nov 1;12(21):6540-6. doi: 10.1158/1078-0432.CCR-06-0140. Clin Cancer Res. 2006. PMID: 17085669

8

Resistance to imatinib: mutations and beyond.

La Rosée P, Deininger MW. La Rosée P, et al. Semin Hematol. 2010 Oct;47(4):335-43. doi: 10.1053/j.seminhematol.2010.06.005. Semin Hematol. 2010. PMID: 20875550 Review.

9

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

La Rosée P, O'Dwyer ME, Druker BJ. La Rosée P, et al. Leukemia. 2002 Jul;16(7):1213-9. doi: 10.1038/sj.leu.2402555. Leukemia. 2002. PMID: 12094245 Review.

10

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Griswold IJ, et al. Among authors: la rosee p. Blood. 2004 Nov 1;104(9):2912-8. doi: 10.1182/blood-2003-05-1669. Epub 2004 Jul 8. Blood. 2004. PMID: 15242881 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters